Suresh Raghavaiah

Learn More
Sensitized renal transplant recipients with high levels of donor-specific alloantibody (DSA) commonly develop antibody-mediated rejection (AMR), which may cause acute graft loss or shorten allograft survival. We examined the efficacy of terminal complement inhibition with the humanized anti-C5 antibody, eculizumab, in the prevention AMR in renal transplant(More)
Terminal complement blockade has been shown to decrease the incidence of early acute antibody-mediated rejection (eAMR) in the first month after positive cross-match kidney transplant recipients, yet some patients still develop eAMR. The current study investigated possible mechanisms of eAMR despite eculizumab treatment. Of the 26 patients treated with(More)
BACKGROUND Donor specific alloantibody producing plasma cells (DSA-PCs) appear resistant to conventional immunosuppressive agents. This study aimed to determine the impact of pretransplant monotherapy with the proteasome inhibitor bortezomib on DSA-PCs in sensitized renal allograft candidates and to assess if DSA-PC depletion would enhance the efficacy of(More)
PURPOSE OF REVIEW To outline recent advances in our understanding of the role of B cells in transplantation. RECENT FINDINGS While T-cell-mediated alloimmunity has been largely controlled using immunosuppression, the role of B cells in transplantation is just beginning to be understood. Recent studies have outlined some of the important clinical issues(More)
Renal retransplantation after a failed prior kidney and pancreas transplant is being increasingly performed. In these complex cases, both iliac fossae have been used for prior transplants, and the placement of the new allograft can be problematic. We describe our experience with an alternative technique for renal retransplantation (RRTx) in the setting of(More)
Even high grade liver injuries in a haemodynamically stable patient are currently treated by NOPM [1-3]. With improvements in imaging techniques and the availability of angio-embolisation, surgical management of liver trauma is limited to damage control surgery and management of complications following NOPM. Delayed bleeding from the liver is one of the(More)
BACKGROUND Eculizumab, a potent inhibitor of terminal complement activation, appears promising in reducing early antibody-mediated rejection in positive crossmatch kidney transplantation. However, its concomitant use with polyclonal rabbit antithymocyte globulin (rATG) might reduce the efficacy of rATG. This study aimed to evaluate the effect of eculizumab(More)
  • 1